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We report the first successful use of irreversible electroporation for the minimally invasive treatment of aggressive cutaneous
tumors implanted in mice. Irreversible electroporation is a newly developed non-thermal tissue ablation technique in which
certain short duration electrical fields are used to permanently permeabilize the cell membrane, presumably through the
formation of nanoscale defects in the cell membrane. Mathematical models of the electrical and thermal fields that develop
during the application of the pulses were used to design an efficient treatment protocol with minimal heating of the tissue.
Tumor regression was confirmed by histological studies which also revealed that it occurred as a direct result of irreversible
cell membrane permeabilization. Parametric studies show that the successful outcome of the procedure is related to the
applied electric field strength, the total pulse duration as well as the temporal mode of delivery of the pulses. Our best results
were obtained using plate electrodes to deliver across the tumor 80 pulses of 100 ms at 0.3 Hz with an electrical field
magnitude of 2500 V/cm. These conditions induced complete regression in 12 out of 13 treated tumors, (92%), in the absence
of tissue heating. Irreversible electroporation is thus a new effective modality for non-thermal tumor ablation.
Citation: Al-Sakere B, Andre ´ F, Bernat C, Connault E, Opolon P, et al (2007) Tumor Ablation with Irreversible Electroporation. PLoS ONE 2(11): e1135.
doi:10.1371/journal.pone.0001135
INTRODUCTION
Minimally invasive tissue ablation has become of central
importance in the modern surgery armamentarium. In the
treatment of benign or malignant tumors it is important to
achieve ablation of the undesirable tissue in a well-controlled and
precise way without affecting the surrounding healthy tissue. As an
alternative to surgical resection, a number of minimally invasive
methods have been developed to destroy specific areas of
undesirable tissues. Most of these techniques are thermal using
cold, e.g. cryosurgery [1–3] or heat, e.g. radiofrequency [4,5].
Electroporation, also knownas electropermeabilization, is a term
used to describe the permeabilization of the cell membrane as
a consequence of the application of certain short and intense
electric fields across the cell membrane, the cells or the tissues. The
permeabilization can be temporary (reversible electroporation) or
permanent (irreversible electroporation) as a function of the
electrical field magnitude and duration, and the number of pulses
[6]. Reversible electroporation is commonly used in vitro to
facilitate the penetration of various otherwise non-permeable
macromolecules across the cell membrane [7–9]. Irreversible
electroporation, the ability of certain electrical pulses to perma-
nently permeabilize the cell membrane, has been known for over
three decades. For most of this period irreversible electroporation
(IRE) was used primarily for ablation of microorganisms and cells
in vitro and studied only as an upper limit of electrical parameters
for reversible tissue electroporation applications. Our group has
pursued the understanding of the electrical fields and processes
that produce IRE with single cell micro-electroporation technol-
ogy [10,11].
The study of Davalos, Mir and Rubinsky, which showed that
IRE can ablate substantial volumes of tissue without inducing
a thermal effect and therefore serve as an independent and new
tissue ablation modality, opened the way to the use of IRE in
surgery [12]. Subsequently, Edd et al. demonstrated tissue ablation
with IRE in vivo in the normal liver of rats. [13]. Complete ablation
of the targeted liver tissue was achieved by exposing the tissue to
electrical parameters that do not induce thermal damage [13].
Massive blood vessel congestion was observed in the sinusoids of
the treated volume, which should significantly enhance the
treatment. The study concluded that IRE produces precisely
delineated ablation zones with cell scale resolution between
ablated and non-ablated areas and the ability of mathematical
modelling to precisely predict the ablated area. A more recent
study was performed to evaluate the long term effects of IRE in
a large animal model [14]. The results demonstrated the ability of
electroporation to ablate large volumes of tissue using electrical
parameters that while substantially above those conventionally
used in reversible electroporation do not induce substantial
thermal effects. The histology has reconfirmed the results in
Davalos et al. [12] and Edd et al. [13] showing that mathematical
modeling of electrical and thermal fields are a powerful tool in
designing IRE ablation protocols, that IRE can be used to ablate
tissue with cell scale resolution and that indeed IRE affects only
the cell membrane and therefore spares connective tissue. Another
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large blood vessels and, unlike thermal ablation, is not affected by
blood flow in these vessels. This implies that IRE could become an
important modality for treatment of tumors near blood vessels.
IRE is a member of a family of non-thermal methods to ablate
tissue with electrical pulses, which includes electrochemotherapy
(ECT) [7,15–18] and supra-poration [19–21]. ECT is a relatively
new minimally invasive tissue ablation technique that employs
reversible electroporation pulses (typically a sequence of eight
100 ms pulses of approximately 1000 V/cm) to reversibly
permeabilize the cell membrane and thereby facilitate the
penetration into cells of small amounts of non-permeant or low-
permeant anti-cancer drugs, such as bleomycin or cisplatin. A
major advantage of ECT is that the technique selectively kills,
through the use of bleomycin, only the dividing tumour cells and
spares the normal non-dividing cells. However, by its nature, ECT
requires of the use of chemical agents, which IRE does not. In
tissue ablation, ECT is proven to be a safe and highly efficient
method to introduce non-permeable cancer drugs into malignant
cells and is currently used to treat cutaneous and subcutaneous
tumors in humans [15,16,22–24]. The standard operating
procedures [17] have been established after a clinical multicenter
study [18] and several previous single center clinical trials, as
reviewed by G. Sersa [25].
Supra-poration, another non-thermal method to kill tissue, is
achieved by means of nanosecond electrical pulses in the tens of
nanoseconds range and 40–80 kV/cm of field strength [19,20]. R.
Nuccitelli et al. [26] described antitumor effects in mice when
nanosecond pulses were delivered in two sets consisting of three
consecutive days of treatment separated by two to three weeks. In
supra-poration, which also does not employ chemical agents, the
pulses delivered are much shorter and the magnitude of the field is
higher by an order of magnitude than in IRE. In supra-poration
cell death is not a consequence of the irreversible cell membrane
permeabilization as in IRE, but the probable result of Ca
2+ ions
released inside the cells from internal Ca
2+ storage vesicles
permeabilized by the nanosecond pulses [20]. Each of these new
techniques based on the non thermal delivery of electric pulses,
namely ECT, IRE and supra-poration, has inherent advantages
and disadvantages for tissue ablation and it is quite likely that each
will find appropriate uses in modern medicine, separately or in
combination.
The present study is the first report of an attempt to evaluate the
effectiveness of IRE in treatment of tumors in vivo using preclinical
mouse models. Our goal was to determine whether IRE alone,
with minimal thermal effects, could actually produce substantial
tumor ablation. We also analyzed the cell death and the changes in
the vasculature in the treated tissue. The results presented in this
study provide further evidence that IRE may become an
important minimally invasive modality for treatment of cancer.
METHODS
Tumour cells culture and tumour production
Cells from a LPB cell line, a methylcholanthrene-induced C57Bl/
6 mouse sarcoma cell line [27], were cultured using standard
procedures in MEM (Gibco BRL, Cer-gy-Pontoise, France)
supplemented with 100 U.ml
21 penicillin, 100 mg.ml
21 strepto-
mycin (Sarbach, France) and 8% foetal calf serum (Gibco). C57Bl/
6 female mice, 6–8 weeks old, were inoculated subcutaneously in
the left flank with 1610
6 cells, producing in 9 days tumors of 4 to
5mm in diameter. Animals were housed at IGR, handled
according to the recommended guidelines [28] and protocols
approved at IGR.
Tumour treatment
At the start of the procedure mice were anaesthetised using
a mixture of xylazine 12.5 mg.kg
21 (Bayer Pharma, Puteaux,
France) and ketamine 125 mg.kg
21 (Parke Davis, Courbevoie,
France). An incision was performed on the skin near the tumor
and the skin flap containing the tumor was lifted, taking
particular care to avoid cutting the main blood vessels nourishing
the tumor. Stainless-steel plate electrodes were placed in direct
contact with both sides of the cutaneous tumor, with the tumor
sandwiched between the parallel plates. Good contact of the
electrodes with the tumor tissue was produced using electrocar-
diography paste (Eko-gel, Camina, Egna, Italy). The distance
between the electrodes ranged from 3 to 5 mm and was adjusted
to tumour size. The spacing between the electrodes was
measured and the information was used to set the voltage
delivered by the pulse generator, so as to produce the design field
magnitude across the tumor, planned for the experiment. The
electrical parameters used in the various experiments are listed in
Table 1. The square-wave electric pulses (EP) were generated by
an electroporation power supply, a Cliniporator
TM (Igea, Carpi,
Italy) or, to deliver pulses with a frequency of 0.3 Hz, a GHT
1287 (Jouan, St Herblain, France ). To obtain a pulse application
frequency of 0.03 Hz, pulses were manually delivered by the
operator every 33 s. After EP delivery, the skin incisions were
closed with metallic clips, the mice were returned to their cages
and the evolution of the treated tumors was followed with
measurements of tumor size every second day. Alternatively,
mice were kept for different periods of time (between 1 and 72 h)
and then humanely sacrificed by CO2 inhalation before the
tumors were removed and processed for histological or
immunohistochemical analysis.
Numerical model of temperature distribution and
thermal dose assessment
Electrical fields produce thermal effects due to Joule type
electrical energy dissipation. Thermal damage occurs when
tissue is exposed to a temperature higher than the physiological
temperature for an extended period of time. In electroporation
the tissue temperature fluctuates during the application of the
pulses and between the pulses. For situations involving
fluctuations of temperature, an analytical procedure was
developed in which thermal damage is assessed by treating the
tissue as if it was at a constant temperature, typically 43uC, for
a duration that would result in an equivalent thermal effect to
the fluctuating temperature [29]. The following expression is
used to calculate the duration necessary to hold the tissue at
43uC to result in an equivalent thermal dose to a fluctuating
temperature:
t43~
X t~final
t~0
R(43{Tt)Dt ð1Þ
where Tt is the average temperature during Dt with R=0.25
when Tt#43uCa n dR=0.5whenTt.43uC [30,31] In order to
calculate the equivalent thermal dose for each experimental
condi-tion, the temperature within the tissue as a function of
time was estimated from the Pennes bioheat transfer equation
[29] with the addition of a Joule heating term as described in
detail in [32].
A one-dimensional explicit transient finite difference model was
created to estimate the heating associated with each electropora-
tion procedure [33]. The model geometry was representative of
Tumor Ablation with IRE
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electrodes, in which the distance between the parallel electrodes
was typically 4 mm. The problem was solved under the
assumption that the electroporation electrode side facing away
from the tumor is cooled by convection heat transfer with the
surrounding air and is treated as an infinite fin as described in
[32]. The free convection heat transfer coefficient was taken as
15 W m
22K
21, and the ambient air, as 25uC [34]. It is assumed
that the tissue and the electrode are initially at 37uC and 25uC,
respectively.
The values for the tissue heat capacity (4 kJ kg
21K
21), electrical
conductivity (0.2 S m
21), thermal conductivity (0.5 W m
21K
21)
and density (1000 kg m
23) are taken from the literature for mouse
fibrosarcoma tissue 7 days after inoculation of the tumor cells
[35,36]. The values for the electrode heat capacity
(477 J kg
21K
21), electrical conductivity (2,222,222 S m
21), ther-
mal conductivity (14 W m
21K
21) and density (7900 kg m
23) are
for 304 stainless steel [37]. The metabolism was assumed to be
33,800 W m
23 [35] and blood flow was neglected because of the
results presented by Edd et al. which show that perfusion stops
during such a procedure [13]. For the experiments with immune-
competent mice that had a delay between pulse trains (see Table 1),
a 45 second delay was used. For the scenarios with immune-
deficient mice, no delay between pulse trains was assumed.
Histology, immunohistochemistry and DNA break
detection
For haematoxylin–eosin-saffron (HES) staining Tumors
were fixed in Finefix (Milestone, Italy) and embedded in paraffin.
Sections of 4 mm were prepared for routine HES staining.
For immunohistochemistry of microvessels CD31 Paraffin
sections (4 mm-thick) were dewaxed and rehydrated. Endogenous
peroxidase activity was quenched by 3% H2O2 for 10 min. Sections
were placed in cover-plates (Shandon, Life Sciences Technology,
Cergy-Pontoise, France) and incubated with blocking serum Power
Block 1:10 (BioGenex, San Ramon, CA, USA) for 10 min. The
slides were then incubated for 1 h with purified rat-anti-mouse
monoclonal anti-platelet endothelial cell adhesion molecule
(PECAM-1 also called CD31), dilution 1:300, (PharMingen,
Heidelberg, Germany) followed by rabbit anti-rat
immunoglobulins (Dako Denmark) dilution 1:200, for 30 min,
followed by PowerVision poly-HRP anti-Rabbit IgG
(ImmunoVision Technologies, Brisbane, CA) for 20 min. Finally,
slides were exposed to diaminobenzidine chromogenic substrate
(DAB PowerVision Histostaining Kit; ImmunoVision Technologies)
for 10 min, washed with distilled water, counterstained with Mayer’s
hematoxylin, and mounted in permanent medium (Pertex). All slides
were immunolabelled the same day to ensure standardized intensities
of immunochemical signals and counterstaining.
TUNEL (Terminal deoxynucleotidyl transferase
(TdT)-mediated dUTP Nick End-Labeling)
Double Strand DNA breaks, which are often associated with cell
apoptosis, were detected using the ‘‘In Situ Cell Death’’ Detection kit
(Roche; Mannheim, Germany) (TUNEL method) performed
according to the manufacturer’s instructions. De-paraffinized
sections were incubated with Citrate buffer, pH 6 and placed in
a water-bath, 98uC for 40 min and all sections were treated with
TUNEL reagents (TUNEL mixture: 1 hour at 37uCu n d e r
a coverslip) except for one where the enzyme was omitted (negative
control). After washings with Rince Buffer Biogenex, slides were
incubated with the secondary anti-fluorescein-AP conjugate, and the
signal was revealed with Fast Red substrate solution for 20 min.
Slides were lightly counterstained with hematoxylin prior to aqueous
mounting by Aqua-Perm (Shandon Aqua-Perm
TM Thermo Electron
IVDD Compliant, Waltham, MA).
RESULTS
Antitumour effects of irreversible electroporation
Effects on tumors transplanted in immunocompetent
mice Several electrical pulse parameters (Table 1) were tested
Table 1. Details of the experimental conditions tested and summary of the antitumor effects achieved.
..................................................................................................................................................
Exp N t [ms] U/d [V/cm] d [mm] f [Hz] Tmax [uC] t43 [s] CR
a: IMMUNOCOMPETENT MICE (Figure 1)
1B 1 800 2000 3 or 5 1 39 0.01 0/7 (0%)
1C 8 100 2000 3 or 5 1 38 0.002 0/7 (0%)
1E 8 (462) 800 2000 5 1 43 0.6 0/6 (0%)
1F 64 (1664) 100 2000 5 5000 40 0.03 1/6 (17%)
1H 8 (462) 800 2500 4 1 46 30 3/6 (50%)
1I 64( 1664) 100 2500 4 5000 41 0.3 2/6 (33%)
1K 64(1664) 100 2500 4 1 38 0.004 3/8 (37%)
1L 8 (462) 1000 2500 4 0.3 51 1300 5/8 (62%)
b: IMMUNODEFICIENT MICE (Figure 2)
2B 8 (462) 1000 2500 4 0.3 51 1300 2/13 (15%)
2C 80 (4620) 100 2500 4 3 40 0.1 11/16 (69%)
2E 8 (462) 1000 2500 4 0.03 40 0.05 4/13 (31%)
2F 80 (4620) 100 2500 4 0.3 37.5 0.001 12/13 (92%)
In all experiments except 1B and 1C, the pulses were delivered in 2 perpendicular orientations. The EP were delivered using a Cliniporator in all conditions except 1L, 2B
and 2F for which a Jouan device was used (see Methods). Exp: experimental condition; n: number of pulses; t: individual pulse duration; U/d: voltage to distance ratio
(approximate electric field strength); d: distance between the plate electrodes; f: repetition frequency; Tmax: theoretical maximum temperature; t43: theoretical
equivalent thermal dose; CR: number of complete regressions/number of treated tumors, and percentage of CR.
doi:10.1371/journal.pone.0001135.t001
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initial parameters tested were derived from electrical parameters of
reversible electroporation and employed an electric field (voltage
to electrodes distance ratio) of 2000 V/cm and 800 ms total
duration of the electric pulses (EP). These conditions did not result
in any complete regression but, for some of the treated tumors,
a slow-down of growth was recorded (Table 1 and Fig. 1B and
1C).
We tested additional modes of application of electrical pulses. In
the following set of tests the EP were delivered in two
perpendicular directions for a more complete coverage of the
tumor. In some tests the number of EP was increased. These
changes were only partly efficient as a slow down in tumour
growth was again noticed but no complete regression (CR) was
achieved, except for one single tumor (Table 1 and Fig. 1E and
1F). The major increase in efficacy on tumor regression resulted
from the increase of the ratio of the applied voltage to electrodes
distance. The voltage-to-distance ratio is used to characterize the
‘‘average’’ electric field strength in the tissue. The actual electric
field in each point of the tissue depends on the geometry of the
electrodes (not only the distance between the electrodes but also
their shape and dimensions) and on the applied voltage. At
2500 V/cm, between 33% and 67% of complete regressions were
achieved in the four experimental conditions tested (Table 1,
Fig. 1H, 1I, 1K, and 1L). The efficacy does not seem to be related
to the frequency, either 1Hz or 5000 Hz (Figs. 1I and 1K), at
which the electric pulses were delivered.
Effects on tumors transplanted in immunodeficient
mice Similar results to those discussed above were achieved
with tumors transplanted in nude mice to assess whether the host
immune system has a low or moderate participation in the
antitumor effects observed. A supplementary study confirmed that
the immune response is not instrumental for IRE ablation which
broadens the potential application space for IRE treatment to
immunodepressed patients [38]. Another interesting point is that
two different regimes were applied (80 EP of 100 ms versus 8 EP of
1000 ms; Table 1 and Fig. 2B and 2E, and 2C and 2F) which were
characterized by the same EP total duration and by the same total
treatment duration (26.7 s, 2B and 2C, or 267 s, 2E and 2F). The
most effective electroporation parameters proved to be condition
2F that led to 12 CR out of 13 mice treated.
Analysis of thermal effects in the treated tumors Table 1
contains two columns of results from the analysis of the thermal
effects. One of the columns gives the maximum temperature
associated with each procedure, and the second contains the
duration required to maintain the tissue at 43uCi no r d e rt o
achieve an equivalent thermal dose as the procedure. The results
are for the centerline, which is where the maximal temperature
develops and can be considered as an upper limit. The analysis
shows that the time delay between pulse trains allowed for
significant heat dissipation through the electrodes. The results
show that the heating was insignificant for cases 1B, 1C, 1E, 1F,
1I, 1K, 2C, 2E, 2F and most likely did not play a role during
cases 1H, 1L and 2B. Since the model does not account for
convective heat dissipation out of the sides and top of the tumor
or of conduction though the animal itself, it is conservative
and provides upper limits of the temperature increase in the
tissue.
Figure 1. Determination of appropriate electrical parameters for an effective tumor treatment by IRE – experiments with immunocompetent
mice. Panels are identified by letters corresponding to the parameters described in table 1, except for panel A (tumor growth in untreated mice
followed as controls of treatment conditions B and C), panel D (control of E and F), panel G (control of H and I) and panel J (control of K and L).
doi:10.1371/journal.pone.0001135.g001
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Evolution of the tumor cell morphology and tumor
structure In the untreated control tumors, cells display a large
nucleus surrounded by a well marked cytoplasm and a well defined
cell membrane (Fig 3A). The slides stained with the classical HES
staining revealed that 5 min after the EP, no change in tumour cell
morphology was detectable. However, the congestion of blood in
the tumour vessels was evident. This effect is similar to the
irreversible electroporation consequences in the liver described by
Edd et al. [13]. Few changes in tissue architecture and cell
morphology were detected 1 h and 2 h later (Fig 3B and 3C).
However, 6 h after the EP, dramatic changes were observed
(Fig 3D). Cytoplasmic limits between the cells were barely
distinguishable in several parts of the tumour. The nuclei were
still visible, but in a sort of syncytium in these parts of the tumour.
At 24 h, almost the entire tumor presented this image (Fig 3F).
The nuclei, extremely pycnotic, appeared to be all in the same
‘‘cytoplasm’’ as no limit was detectable between the original cells.
At 48 h (Fig 3F) and 72 h, the nuclei were even smaller and tissue
necrosis still more evident.
Analysis of cell death in the treated tumors TUNEL
staining revealed that in the control slides, very few cells were
stained positive. The staining was strictly localized at the level of
the cell nucleus (Fig 4A). Background was very clear (Fig 4A).
However, as early as 5 min after the treatment, changes began,
albeit slightly noticeable: a larger number of nuclei were positive,
and in many of these nuclei, staining was not contained inside the
nucleus, but was clearly spreading in the cytoplasm (Fig 4B).
Background was still very clear (Fig 4B). The overall staining of the
slices increased 1 h after EP delivery. There was a clear increase in
the number of red-dye leaking cells and there was also the
presence of a red background (Fig 4C). Thus, two types of staining
can be clearly identified in these slices and at later times. At 6 h,
a large number of cells still display the diffuse staining (not shown).
However, at longer times (24 h, Fig 4D), there was only a heavily
red-stained background, which completely diffused and continued
to spread throughout the entire tumor section. At 24 h, no more
red-dye leaking cells were found, in agreement with the HES
images that showed the complete disintegration of the cells.
Figure 2. Determination of appropriate electrical parameters for an effective tumor treatment by IRE – experiments with immunodeficient
(nude) mice. Panels are identified by letters corresponding to the parameters described in table 1, except for panel A (tumor growth in untreated
mice followed as controls of treatment conditions B and C) and panel D (control of treatments E and F).
doi:10.1371/journal.pone.0001135.g002
Figure 3. Analysis of tumor evolution by HES histological staining
after IRE. A: control; B, C, D, E and F: respectively 1, 2, 6, 24 and 48 h
after IRE.
doi:10.1371/journal.pone.0001135.g003
Figure 4. TUNEL analysis at different times after the pulses delivery.
A: control; B, C and D: respectively 5 min and 1 and 24 h after IRE.
doi:10.1371/journal.pone.0001135.g004
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detectable immediately after treatment in the HES slides,
evolution of the tumour vasculature was also analysed using
antibodies against the CD31 endothelial cells specific marker
(Fig. 5). The changes in vasculature, which were observed 5 min
after EP delivery were slight with respect to the controls (Fig. 5A),
displayed highly branched and tortuous vasculature typical to this
well vascularized fibrosarcoma tumor. However, 2 h later, well
established vascular congestion with dilated vessels was detectable,
long vessels were not visible and a slight diffuse staining began to
spread in some parts of the slices. At 6 h, blood vessel walls, when
still present, were either hyper- or hypo-pigmented. The diffusion
of the CD31 marker in the extra-cellular interstitial spaces was
much more intense and micro-vascular occlusions were also
detectable. These signs indicate advanced tumour vasculature
lesions. At 24 h, very advanced vascular lesions were seen, with
faint CD31 marker staining of the endothelial cells indicating
damaged blood vessel walls, and intense diffusion of the staining in
the whole tissue. What remained were blood vessel skeletons over
a necrotic background.
DISCUSSION
Our results provide evidence that IRE can be used to ablate
tumors in vivo. The results achieved with the different sets of
electrical parameters indicate that the main parameter affecting
the results is the electric field strength. Trains of a large number of
short pulses resulted in the best antitumor effects (up to 92% of
tumor ablation).
From previous studies on the electric field distribution during
electroporation in vivo [13,39–41], the electrodes type (plates,
different types of needle arrays) and the adequacy with which the
IRE electrical field affects the totality of the tumor volume will be
crucial parameters in achieving successful tumor ablation. In our
study the electric pulses were delivered through parallel plates in
direct contact with the tumor tissue, which is a configuration that
ensures a rather homogeneous electrical field throughout the
tumor [39–41]. Therefore, the values used in this study for the
voltage to distance ratio are actually a good measure for the field
that has developed in the treated tumors.
This study has produced several observations concerning the
mechanisms of cell ablation in the IRE method as well as evidence
of the efficacy of IRE to completely destroy aggressive tumors. As
shown in normal liver tissue [13], classical HES staining revealed
that the IRE pulses induce vascular congestion, which should also
cause tissue hypoxia and may further contribute to tumor cell
death. Twenty-four hours after the application of the pulses, all
treated tissue was necrotic. Interestingly, the treatment does not
produce massive apoptosis. The number of nuclei stained by the
TUNEL reaction slightly increases 1 h after the treatment. The
original and remarkable observation reported is the detection of
diffused TUNEL staining first in the cytoplasm around the cell
nucleus, and later, around the cells. In fact, this diffused staining,
that constitutes almost the only TUNEL staining a few hours after
the EP, is consistent with the expected effects of the applied IRE
pulses. Indeed if irreversible electroporation is actually achieved,
the plasma membrane should not reseal and there is also
a possibility of affecting the nuclear envelope. Thus, DNA
becomes accessible to extracellular nucleases (the DNA double
strand breaks (DSB) are the seeding point for the TUNEL
staining). Then DNA can spread out of the nucleus and out of the
cell (facilitating the generation of DSB, the DSB themselves
facilitating DNA spreading out of the nucleus). The observation of
a diffused TUNEL staining corroborates that cells are no longer
limited by their natural membrane barrier, which is indeed the
hallmark of irreversible electroporation.
The analysis of the CD31 staining confirmed that membrane
alteration due to IRE is the basis for the efficacy of the treatment.
Initially, this staining was meant for the study of the evolution of the
tumor vasculature disruption. Our results show rapid and severe
lesions of the vasculature. They also reveal that the disaggregation of
the membranes starts a couple of hours after the pulse delivery and
becomes very intense 6 h later, and is complete at 24 h. The
localization of the membrane antigen CD 31 at the cell membrane
is progressive and becomes complete. We find that the antigen
diffuses throughout the treated tumor volume, indicating the
complete disruption of the membranes as well as cell necrosis.
The goal of our study was to evaluate the ability of the IRE
electrical pulses to produce cell ablation through their effect on the
cell membrane. However, electrical pulses can also have a thermal
effect through electrical Joule heating. Since heating is also a well
known mechanism for cell ablation, we designed our studies in such
a way that the IRE electrical pulses we used produced the desired
effect on the cell membrane without having a substantial thermal
effect. Therefore, in treatment planning we designed for a mild and
benign increase in temperature and used a very conservative
mathematical model in the analysis, which does not account for
convective heat dissipation through the air or conduction through
the animal. With regards to the effects of temperature, it is
interesting to compare the experiments 2B and 2C (Table 1 and
Fig 2). According to our calculations, eight 1000 ms pulses produce
more heating than eighty 100 ms pulses. A larger percentage of CR
was achieved with the eighty 100 ms pulses than with the eight
1000 ms pulses. Thus, we can infer that heating cannot be the cause
of tumor regression in IRE. Moreover, the higher tumor regression
efficacy achieved by applying the same energy in a sequence of
shorter pulses to induce less of a thermal dose is consistent with
results achieved in vitro by Miller et al. [42]. In their study, 10 pulses
of 0.3 ms (at 1500 V/cm) were more efficient in cell killing in vitro
than 1 pulse of 3 ms (identical total duration) at the same voltage-to-
distance ratio. Miller et al. also showed that complete cell killing was
achieved using 3 sets of 10 pulses of 0.3 ms [42]. This results in
a total pulse duration of 9 ms which is very close to the 8 ms used in
vivo in our experiments.
Figure 5. Immunohistochemical analysis of the tumour vasculature
evolution by means of CD 31 staining in LPB tumors after treatment.
A: control; B, C and D: respectively 2, 6 and 24 h after IRE.
doi:10.1371/journal.pone.0001135.g005
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and 2F) were chosen to yield an almost negligible thermal effect.
The two experiments with 80 and 8 pulses yield an equivalent
thermal dose of less than 1 s at 43uC. Even though it takes several
tens of minutes of exposure at 43uC to retard the growth of murine
fibrosarcoma [43,44], condition 2F resulted in an impressive 92%
of CR. Therefore our results, taken together, verify that the
antitumor effects of IRE are not thermal. For an identical total
energy delivery at the same electrical field, a large number of short
pulses, which produce an overall lower tissue temperature, seem
more effective than the use of a lower number of longer pulses.
Furthermore, the use of long delays between pulses, which allows
the tissue to cool, yields an overall lower tissue temperature
thereby producing a very effective treatment.
In conclusion, our study has produced the first evidence that
IRE can be used to effectively ablate tumors in vivo. Even though
our results are encouraging, future studies can be conducted to
optimize the results and explore the entire parameter space for this
treatment. Nevertheless, the results achieved with different sets of
electrical parameters suggest that the main parameters affecting
the success of the treatment are not only the electric field strength,
but also the number of pulses and the total pulse duration. The
histological and immunohistochemical findings reported, as well as
the theoretical arguments linked to the use of a high number of
short pulses at a very low repetition frequency, demonstrate that
tumor ablation is actually due to irreversible permeabilization of
the tumor cells and not to excessive heating. It is worthy to note
that TUNEL analysis of the cell death and CD31 analysis of the
tumor vasculature evolution revealed not only the necrotic
pathway of the IRE-caused cell death, but also confirms the
mechanisms of the method, that is the actual irreversible
electroporation of the cell membrane and its consecutive
disintegration. This manuscript thus reports all the parameters
necessary to bring IRE towards clinical trials that should help in
defining the indications of this new cancer treatment.
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